Studybox Research Dual Submission Studies
Syphilis Rapid Test
One integrated study supporting both 510(k) clearance and CLIA waiver.
Studybox
Dual Submission Studies
Syphilis incidence in the United States rose sharply over the past decade, including congenital syphilis, and same-visit treponemal testing has an obvious role. The clinical study is a serology comparison with a complication: treponemal antibodies persist for life in most people after treatment, so a reactive result cannot distinguish active from past infection. Study subjects must be characterized by stage and treatment history, and the labeling will describe the test as an aid to diagnosis requiring confirmatory and nontreponemal follow-up.
Sensitivity in primary syphilis is lower for all treponemal tests because antibodies are still developing, and this stage is where a rapid test has the most clinical value and the fewest study subjects. Enrollment typically relies on sexual health clinics and emergency departments with high syphilis volume, supplemented with characterized banked sera for staging strata that are hard to enroll prospectively.
- Analyte
- Treponema pallidum antibodies (treponemal), with some devices adding a nontreponemal component
- Therapeutic area
- STD/STI Detection
- Specimens
- Capillary Fingerstick Blood, Venous Whole Blood, Serum and Plasma
- Intended-use settings
- urgent care, physician office, pharmacy, emergency department
- Operators
- Non-laboratory clinic staff in waived settings; laboratory staff for moderate-complexity claims.
- Comparator
- Typically laboratory treponemal serology (a treponemal immunoassay and/or T. pallidum particle agglutination) with nontreponemal testing (RPR or VDRL with titer) and clinical staging; subjects are classified by a composite of serology and clinical history.
Dual Submission specifics
What Changes for This Assay on This Pathway.
- A single prospective study at waived sites with untrained operators, plus a retrospective staged-sera arm reported separately, supports both components.
- The stage-specific sensitivity analysis applies to the 510(k) half; the waiver half emphasizes overall agreement and specificity in untrained hands, and both must hold in the same population.
- Venous blood, serum and plasma claims are typically supported by laboratory matrix studies attached to the 510(k) half, while fingerstick carries the waiver.
Endpoints the study must support
- Sensitivity by disease stage (primary, secondary, early latent, late latent, previously treated) against the laboratory treponemal reference, with 95% confidence intervals
- Specificity in a low-prevalence population without history of syphilis
- Agreement across claimed specimen types (fingerstick, venous whole blood, serum, plasma)
- Invalid rate and inter-operator agreement in waived settings
Enrollment realities
Driven by prospectively enrolled primary and secondary syphilis cases, which are uncommon even at high-volume clinics; banked staged sera are typically needed. Specificity enrollment at low-prevalence waived sites accrues quickly.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run dual submission studies →
Same assay, other pathways
Relevant FDA guidance
- Recommendations for Dual 510(k) and CLIA Waiver by Application Studies
- Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices
- Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
FAQ
Syphilis Rapid Test Study Questions.
01 Who operates the syphilis rapid test in a dual submission study?
Non-laboratory clinic staff in waived settings; laboratory staff for moderate-complexity claims.
02 What is the comparator for a syphilis rapid test study?
Typically laboratory treponemal serology (a treponemal immunoassay and/or T. pallidum particle agglutination) with nontreponemal testing (RPR or VDRL with titer) and clinical staging; subjects are classified by a composite of serology and clinical history.
03 What drives enrollment for a syphilis rapid test study?
Driven by prospectively enrolled primary and secondary syphilis cases, which are uncommon even at high-volume clinics; banked staged sera are typically needed. Specificity enrollment at low-prevalence waived sites accrues quickly.
Let's talk IVD research
Planning a syphilis rapid test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the dual submission pathway.